#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	Higher	_
1-2	7-13	Social	_
1-3	14-23	Rejection	_
1-4	24-35	Sensitivity	_
1-5	36-38	in	_
1-6	39-55	Opioid-Dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-7	56-64	Patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-8	65-67	Is	_
1-9	68-75	Related	_
1-10	76-78	to	_
1-11	79-86	Smaller	_
1-12	87-93	Insula	_
1-13	94-98	Gray	_
1-14	99-105	Matter	_
1-15	106-112	Volume	_
1-16	113-114	:	_
1-17	115-116	A	_
1-18	117-128	Voxel-Based	_
1-19	129-141	Morphometric	_
1-20	142-147	Study	_
1-21	148-156	Abstract	_
1-22	157-173	Opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-23	174-182	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-24	183-186	are	_
1-25	187-193	highly	_
1-26	194-204	sensitized	_
1-27	205-207	to	_
1-28	208-216	negative	_
1-29	217-223	social	_
1-30	224-232	feedback	_
1-31	233-234	,	_
1-32	235-238	and	_
1-33	239-248	increased	_
1-34	249-255	social	_
1-35	256-265	rejection	_
1-36	266-277	sensitivity	_
1-37	278-281	was	_
1-38	282-288	linked	_
1-39	289-291	to	_
1-40	292-299	adverse	_
1-41	300-309	treatment	_
1-42	310-317	outcome	_
1-43	318-319	,	_
1-44	320-323	but	_
1-45	324-327	its	_
1-46	328-343	neurobiological	_
1-47	344-357	underpinnings	_
1-48	358-362	have	_
1-49	363-366	not	_
1-50	367-371	been	_
1-51	372-382	understood	_
1-52	383-386	yet	_
1-53	387-388	.	_

2-1	389-392	The	_
2-2	393-400	present	_
2-3	401-406	study	_
2-4	407-419	investigated	_
2-5	420-424	gray	_
2-6	425-431	matter	_
2-7	432-433	(	_
2-8	434-436	GM	_
2-9	437-438	)	_
2-10	439-445	volume	_
2-11	446-457	differences	_
2-12	458-465	between	_
2-13	466-468	19	_
2-14	469-475	opioid	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-15	476-487	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-16	488-497	treatment	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-17	498-499	(	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-18	500-503	OMT	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-19	504-505	)	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-20	506-514	patients	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
2-21	515-518	and	_
2-22	519-521	20	_
2-23	522-529	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-24	530-538	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-25	539-544	using	_
2-26	545-553	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-27	554-563	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-28	564-571	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-29	572-575	and	_
2-30	576-587	voxel-based	_
2-31	588-599	morphometry	_
2-32	600-601	.	_

3-1	602-614	Associations	_
3-2	615-617	of	_
3-3	618-620	GM	_
3-4	621-628	volumes	_
3-5	629-633	with	_
3-6	634-644	subjective	_
3-7	645-653	feelings	_
3-8	654-656	of	_
3-9	657-666	exclusion	_
3-10	667-670	and	_
3-11	671-680	inclusion	_
3-12	681-687	during	_
3-13	688-689	a	_
3-14	690-696	social	_
3-15	697-706	ostracism	_
3-16	707-708	(	_
3-17	709-718	Cyberball	_
3-18	719-720	)	_
3-19	721-729	paradigm	_
3-20	730-731	,	_
3-21	732-736	with	_
3-22	737-746	rejection	_
3-23	747-758	sensitivity	_
3-24	759-760	,	_
3-25	761-767	social	_
3-26	768-779	interaction	_
3-27	780-787	anxiety	_
3-28	788-791	and	_
3-29	792-798	social	_
3-30	799-805	phobia	_
3-31	806-810	were	_
3-32	811-819	explored	_
3-33	820-821	.	_

4-1	822-825	OMT	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-2	826-834	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-3	835-844	displayed	_
4-4	845-852	smaller	_
4-5	853-855	GM	_
4-6	856-862	volume	_
4-7	863-865	in	_
4-8	866-869	the	_
4-9	870-879	bilateral	_
4-10	880-886	insula	_
4-11	887-890	and	_
4-12	891-899	inferior	_
4-13	900-907	frontal	_
4-14	908-912	gyri	_
4-15	913-914	.	_

5-1	915-927	Psychometric	_
5-2	928-931	and	_
5-3	932-936	task	_
5-4	937-941	data	_
5-5	942-948	showed	_
5-6	949-953	that	_
5-7	954-962	patients	_
5-8	963-971	reported	_
5-9	972-985	significantly	_
5-10	986-992	higher	_
5-11	993-1002	rejection	_
5-12	1003-1014	sensitivity	_
5-13	1015-1016	,	_
5-14	1017-1023	social	_
5-15	1024-1031	anxiety	_
5-16	1032-1035	and	_
5-17	1036-1042	social	_
5-18	1043-1049	phobia	_
5-19	1050-1056	scores	_
5-20	1057-1060	and	_
5-21	1061-1065	felt	_
5-22	1066-1070	more	_
5-23	1071-1079	excluded	_
5-24	1080-1083	and	_
5-25	1084-1088	less	_
5-26	1089-1097	included	_
5-27	1098-1104	during	_
5-28	1105-1108	the	_
5-29	1109-1115	social	_
5-30	1116-1125	ostracism	_
5-31	1126-1134	paradigm	_
5-32	1135-1136	.	_

6-1	1137-1144	Smaller	_
6-2	1145-1147	GM	_
6-3	1148-1154	volume	_
6-4	1155-1157	in	_
6-5	1158-1161	the	_
6-6	1162-1168	insula	_
6-7	1169-1172	was	_
6-8	1173-1183	associated	_
6-9	1184-1188	with	_
6-10	1189-1195	higher	_
6-11	1196-1206	subjective	_
6-12	1207-1216	exclusion	_
6-13	1217-1218	,	_
6-14	1219-1224	lower	_
6-15	1225-1235	subjective	_
6-16	1236-1245	inclusion	_
6-17	1246-1249	and	_
6-18	1250-1256	higher	_
6-19	1257-1266	rejection	_
6-20	1267-1278	sensitivity	_
6-21	1279-1280	,	_
6-22	1281-1287	social	_
6-23	1288-1295	anxiety	_
6-24	1296-1299	and	_
6-25	1300-1306	social	_
6-26	1307-1313	phobia	_
6-27	1314-1320	scores	_
6-28	1321-1322	.	_

7-1	1323-1331	Findings	_
7-2	1332-1340	indicate	_
7-3	1341-1345	that	_
7-4	1346-1356	structural	_
7-5	1357-1365	deficits	_
7-6	1366-1368	in	_
7-7	1369-1377	emotion-	_
7-8	1378-1381	and	_
7-9	1382-1400	anxiety-processing	_
7-10	1401-1406	brain	_
7-11	1407-1414	regions	_
7-12	1415-1417	in	_
7-13	1418-1421	OMT	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-14	1422-1430	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-15	1431-1434	are	_
7-16	1435-1445	associated	_
7-17	1446-1450	with	_
7-18	1451-1460	increased	_
7-19	1461-1467	social	_
7-20	1468-1477	rejection	_
7-21	1478-1489	sensitivity	_
7-22	1490-1491	.	_

8-1	1492-1494	As	_
8-2	1495-1501	social	_
8-3	1502-1511	rejection	_
8-4	1512-1514	is	_
8-5	1515-1516	a	_
8-6	1517-1526	potential	_
8-7	1527-1534	trigger	_
8-8	1535-1538	for	_
8-9	1539-1546	relapse	_
8-10	1547-1548	,	_
8-11	1549-1557	patients	_
8-12	1558-1563	might	_
8-13	1564-1571	benefit	_
8-14	1572-1576	from	_
8-15	1577-1588	therapeutic	_
8-16	1589-1599	strategies	_
8-17	1600-1604	that	_
8-18	1605-1612	promote	_
8-19	1613-1619	social	_
8-20	1620-1631	integration	_
8-21	1632-1633	.	_

9-1	1634-1643	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1644-1647	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1648-1655	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-4	1656-1668	Participants	_
9-5	1669-1685	Opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
9-6	1686-1694	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
9-7	1695-1699	were	_
9-8	1700-1709	recruited	_
9-9	1710-1712	in	_
9-10	1713-1715	an	_
9-11	1716-1726	outpatient	_
9-12	1727-1733	opioid	_
9-13	1734-1745	maintenance	_
9-14	1746-1753	program	_
9-15	1754-1756	of	_
9-16	1757-1760	the	_
9-17	1761-1768	Central	_
9-18	1769-1778	Institute	_
9-19	1779-1781	of	_
9-20	1782-1788	Mental	_
9-21	1789-1795	Health	_
9-22	1796-1798	in	_
9-23	1799-1807	Mannheim	_
9-24	1808-1809	,	_
9-25	1810-1817	Germany	_
9-26	1818-1819	.	_

10-1	1820-1823	The	_
10-2	1824-1831	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-3	1832-1839	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-4	1840-1845	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-5	1846-1855	consisted	_
10-6	1856-1858	of	_
10-7	1859-1869	volunteers	_
10-8	1870-1874	that	_
10-9	1875-1879	were	_
10-10	1880-1889	recruited	_
10-11	1890-1894	from	_
10-12	1895-1904	newspaper	_
10-13	1905-1908	and	_
10-14	1909-1915	clinic	_
10-15	1916-1924	homepage	_
10-16	1925-1938	advertisement	_
10-17	1939-1940	.	_

11-1	1941-1944	The	_
11-2	1945-1950	study	_
11-3	1951-1954	was	_
11-4	1955-1963	approved	_
11-5	1964-1966	by	_
11-6	1967-1970	the	_
11-7	1971-1976	local	_
11-8	1977-1983	ethics	_
11-9	1984-1993	committee	_
11-10	1994-1996	of	_
11-11	1997-2000	the	_
11-12	2001-2011	University	_
11-13	2012-2014	of	_
11-14	2015-2025	Heidelberg	_
11-15	2026-2029	and	_
11-16	2030-2039	performed	_
11-17	2040-2042	in	_
11-18	2043-2053	accordance	_
11-19	2054-2058	with	_
11-20	2059-2062	the	_
11-21	2063-2074	Declaration	_
11-22	2075-2077	of	_
11-23	2078-2086	Helsinki	_
11-24	2087-2088	,	_
11-25	2089-2092	and	_
11-26	2093-2101	informed	_
11-27	2102-2109	written	_
11-28	2110-2117	consent	_
11-29	2118-2121	was	_
11-30	2122-2130	obtained	_
11-31	2131-2132	.	_

12-1	2133-2136	All	_
12-2	2137-2149	participants	_
12-3	2150-2154	were	_
12-4	2155-2163	required	_
12-5	2164-2166	to	_
12-6	2167-2169	be	_
12-7	2170-2174	aged	_
12-8	2175-2182	between	_
12-9	2183-2185	18	_
12-10	2186-2189	and	_
12-11	2190-2192	65	_
12-12	2193-2198	years	_
12-13	2199-2200	.	_

13-1	2201-2217	Opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
13-2	2218-2226	patients	_
13-3	2227-2230	had	_
13-4	2231-2233	to	_
13-5	2234-2238	meet	_
13-6	2239-2242	the	_
13-7	2243-2252	diagnosis	_
13-8	2253-2255	of	_
13-9	2256-2262	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
13-10	2263-2273	dependence	_
13-11	2274-2283	according	_
13-12	2284-2286	to	_
13-13	2287-2290	the	_
13-14	2291-2296	ICD10	_
13-15	2297-2298	.	_

14-1	2299-2306	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-2	2307-2319	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-3	2320-2324	were	_
14-4	2325-2333	included	_
14-5	2334-2338	only	_
14-6	2339-2341	if	_
14-7	2342-2344	no	_
14-8	2345-2355	indication	_
14-9	2356-2358	of	_
14-10	2359-2368	substance	_
14-11	2369-2374	abuse	_
14-12	2375-2383	disorder	_
14-13	2384-2386	or	_
14-14	2387-2394	another	_
14-15	2395-2401	mental	_
14-16	2402-2409	illness	_
14-17	2410-2413	was	_
14-18	2414-2419	found	_
14-19	2420-2426	during	_
14-20	2427-2429	an	_
14-21	2430-2439	interview	_
14-22	2440-2444	with	_
14-23	2445-2447	an	_
14-24	2448-2459	experienced	_
14-25	2460-2468	clinical	_
14-26	2469-2481	psychiatrist	_
14-27	2482-2483	.	_

15-1	2484-2493	Exclusion	_
15-2	2494-2502	criteria	_
15-3	2503-2506	for	_
15-4	2507-2511	both	_
15-5	2512-2518	groups	_
15-6	2519-2523	were	_
15-7	2524-2525	:	_
15-8	2526-2527	(	_
15-9	2528-2529	i	_
15-10	2530-2531	)	_
15-11	2532-2541	substance	_
15-12	2542-2545	use	_
15-13	2546-2554	disorder	_
15-14	2555-2560	other	_
15-15	2561-2565	than	_
15-16	2566-2574	nicotine	_
15-17	2575-2576	(	_
15-18	2577-2581	only	_
15-19	2582-2585	for	_
15-20	2586-2593	healthy	_
15-21	2594-2602	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-22	2603-2604	)	_
15-23	2605-2606	,	_
15-24	2607-2608	(	_
15-25	2609-2611	ii	_
15-26	2612-2613	)	_
15-27	2614-2623	pregnancy	_
15-28	2624-2625	,	_
15-29	2626-2627	(	_
15-30	2628-2631	iii	_
15-31	2632-2633	)	_
15-32	2634-2640	severe	_
15-33	2641-2649	internal	_
15-34	2650-2652	or	_
15-35	2653-2665	neurological	_
15-36	2666-2675	condition	_
15-37	2676-2679	and	_
15-38	2680-2681	(	_
15-39	2682-2684	iv	_
15-40	2685-2686	)	_
15-41	2687-2704	contraindications	_
15-42	2705-2708	for	_
15-43	2709-2712	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-44	2713-2721	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-45	2722-2723	(	_
15-46	2724-2727	e.g	_
15-47	2728-2729	.	_

16-1	2730-2737	tattoos	_
16-2	2738-2739	,	_
16-3	2740-2745	metal	_
16-4	2746-2754	implants	_
16-5	2755-2756	,	_
16-6	2757-2766	pregnancy	_
16-7	2767-2768	,	_
16-8	2769-2779	pacemakers	_
16-9	2780-2781	)	_
16-10	2782-2783	.	_

17-1	2784-2785	A	_
17-2	2786-2791	total	_
17-3	2792-2794	of	_
17-4	2795-2797	25	_
17-5	2798-2806	patients	_
17-6	2807-2810	and	_
17-7	2811-2813	22	_
17-8	2814-2821	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-9	2822-2830	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-10	2831-2835	were	_
17-11	2836-2844	included	_
17-12	2845-2847	in	_
17-13	2848-2851	the	_
17-14	2852-2859	current	_
17-15	2860-2865	study	_
17-16	2866-2867	.	_

18-1	2868-2870	19	_
18-2	2871-2879	patients	_
18-3	2880-2881	(	_
18-4	2882-2884	18	_
18-5	2885-2890	males	_
18-6	2891-2894	and	_
18-7	2895-2896	1	_
18-8	2897-2903	female	_
18-9	2904-2905	)	_
18-10	2906-2909	and	_
18-11	2910-2912	20	_
18-12	2913-2921	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-13	2922-2923	(	_
18-14	2924-2926	18	_
18-15	2927-2932	males	_
18-16	2933-2936	and	_
18-17	2937-2938	2	_
18-18	2939-2946	females	_
18-19	2947-2948	)	_
18-20	2949-2957	provided	_
18-21	2958-2966	complete	_
18-22	2967-2970	VBM	_
18-23	2971-2979	datasets	_
18-24	2980-2982	of	_
18-25	2983-2993	sufficient	_
18-26	2994-3001	quality	_
18-27	3002-3003	.	_

19-1	3004-3012	Patients	_
19-2	3013-3016	did	_
19-3	3017-3020	not	_
19-4	3021-3028	undergo	_
19-5	3029-3030	a	_
19-6	3031-3037	formal	_
19-7	3038-3047	screening	_
19-8	3048-3051	for	_
19-9	3052-3060	comorbid	_
19-10	3061-3072	psychiatric	_
19-11	3073-3082	disorders	_
19-12	3083-3088	prior	_
19-13	3089-3091	to	_
19-14	3092-3097	being	_
19-15	3098-3106	included	_
19-16	3107-3109	in	_
19-17	3110-3113	the	_
19-18	3114-3121	current	_
19-19	3122-3127	study	_
19-20	3128-3129	;	_
19-21	3130-3137	however	_
19-22	3138-3139	,	_
19-23	3140-3143	all	_
19-24	3144-3152	patients	_
19-25	3153-3157	were	_
19-26	3158-3169	interviewed	_
19-27	3170-3172	by	_
19-28	3173-3176	two	_
19-29	3177-3188	independent	_
19-30	3189-3201	professional	_
19-31	3202-3215	psychiatrists	_
19-32	3216-3218	at	_
19-33	3219-3222	the	_
19-34	3223-3232	institute	_
19-35	3233-3234	,	_
19-36	3235-3237	in	_
19-37	3238-3243	order	_
19-38	3244-3246	to	_
19-39	3247-3251	rule	_
19-40	3252-3255	out	_
19-41	3256-3264	relevant	_
19-42	3265-3273	comorbid	_
19-43	3274-3285	psychiatric	_
19-44	3286-3294	diseases	_
19-45	3295-3296	.	_

20-1	3297-3299	In	_
20-2	3300-3308	addition	_
20-3	3309-3310	,	_
20-4	3311-3319	patients	_
20-5	3320-3324	were	_
20-6	3325-3332	treated	_
20-7	3333-3335	at	_
20-8	3336-3339	the	_
20-9	3340-3350	department	_
20-10	3351-3352	’	_
20-11	3353-3354	s	_
20-12	3355-3361	opioid	_
20-13	3362-3373	maintenance	_
20-14	3374-3378	unit	_
20-15	3379-3382	for	_
20-16	3383-3390	several	_
20-17	3391-3396	years	_
20-18	3397-3401	with	_
20-19	3402-3409	regular	_
20-20	3410-3422	appointments	_
20-21	3423-3427	with	_
20-22	3428-3429	a	_
20-23	3430-3441	specialized	_
20-24	3442-3454	psychiatrist	_
20-25	3455-3459	once	_
20-26	3460-3461	a	_
20-27	3462-3466	week	_
20-28	3467-3470	and	_
20-29	3471-3473	no	_
20-30	3474-3482	clinical	_
20-31	3483-3491	evidence	_
20-32	3492-3495	for	_
20-33	3496-3497	a	_
20-34	3498-3506	comorbid	_
20-35	3507-3518	psychiatric	_
20-36	3519-3527	disorder	_
20-37	3528-3529	.	_

21-1	3530-3538	Patients	_
21-2	3539-3543	were	_
21-3	3544-3547	all	_
21-4	3548-3551	HIV	_
21-5	3552-3560	negative	_
21-6	3561-3562	,	_
21-7	3563-3566	but	_
21-8	3567-3571	four	_
21-9	3572-3576	were	_
21-10	3577-3583	tested	_
21-11	3584-3592	positive	_
21-12	3593-3596	for	_
21-13	3597-3606	hepatitis	_
21-14	3607-3608	C	_
21-15	3609-3614	virus	_
21-16	3615-3616	(	_
21-17	3617-3620	HCV	_
21-18	3621-3622	)	_
21-19	3623-3633	antibodies	_
21-20	3634-3635	.	_

22-1	3636-3644	Fourteen	_
22-2	3645-3653	patients	_
22-3	3654-3658	were	_
22-4	3659-3666	treated	_
22-5	3667-3671	with	_
22-6	3672-3681	methadone	_
22-7	3682-3685	and	_
22-8	3686-3687	n	_
22-9	3688-3689	=	_
22-10	3690-3691	5	_
22-11	3692-3696	with	_
22-12	3697-3710	buprenorphine	_
22-13	3711-3712	,	_
22-14	3713-3716	the	_
22-15	3717-3721	mean	_
22-16	3722-3731	methadone	_
22-17	3732-3743	equivalence	_
22-18	3744-3748	dose	_
22-19	3749-3752	was	_
22-20	3753-3758	63.35	_
22-21	3759-3763	mg/d	_
22-22	3764-3765	(	_
22-23	3766-3767	±	_
22-24	3768-3773	36.26	_
22-25	3774-3778	mg/d	_
22-26	3779-3787	standard	_
22-27	3788-3797	deviation	_
22-28	3798-3799	(	_
22-29	3800-3803	s.d	_
22-30	3804-3805	.	_
22-31	3806-3807	)	_
22-32	3808-3809	)	_
22-33	3810-3811	.	_

23-1	3812-3819	Further	_
23-2	3820-3828	clinical	_
23-3	3829-3832	and	_
23-4	3833-3839	social	_
23-5	3840-3855	characteristics	_
23-6	3856-3859	are	_
23-7	3860-3869	displayed	_
23-8	3870-3872	in	_
23-9	3873-3878	Table	_
23-10	3879-3880	1	_
23-11	3881-3882	.	_

24-1	3883-3885	At	_
24-2	3886-3889	the	_
24-3	3890-3894	time	_
24-4	3895-3897	of	_
24-5	3898-3906	scanning	_
24-6	3907-3908	,	_
24-7	3909-3914	urine	_
24-8	3915-3923	sampling	_
24-9	3924-3927	was	_
24-10	3928-3937	conducted	_
24-11	3938-3940	to	_
24-12	3941-3947	detect	_
24-13	3948-3953	other	_
24-14	3954-3955	(	_
24-15	3956-3970	non-prescribed	_
24-16	3971-3972	)	_
24-17	3973-3985	psychoactive	_
24-18	3986-3996	substances	_
24-19	3997-3998	(	_
24-20	3999-4002	see	_
24-21	4003-4008	Table	_
24-22	4009-4010	1	_
24-23	4011-4012	)	_
24-24	4013-4014	,	_
24-25	4015-4018	and	_
24-26	4019-4020	9	_
24-27	4021-4024	out	_
24-28	4025-4027	of	_
24-29	4028-4030	19	_
24-30	4031-4039	patients	_
24-31	4040-4048	reported	_
24-32	4049-4051	to	_
24-33	4052-4055	use	_
24-34	4056-4066	substances	_
24-35	4067-4072	other	_
24-36	4073-4077	than	_
24-37	4078-4081	the	_
24-38	4082-4092	prescribed	_
24-39	4093-4099	opioid	_
24-40	4100-4101	(	_
24-41	4102-4111	methadone	_
24-42	4112-4114	or	_
24-43	4115-4128	buprenorphine	_
24-44	4129-4130	)	_
24-45	4131-4132	,	_
24-46	4133-4137	such	_
24-47	4138-4140	as	_
24-48	4141-4156	benzodiazepines	_
24-49	4157-4158	,	_
24-50	4159-4166	cocaine	_
24-51	4167-4168	,	_
24-52	4169-4176	alcohol	_
24-53	4177-4179	or	_
24-54	4180-4188	cannabis	_
24-55	4189-4190	.	_

25-1	4191-4196	Study	_
25-2	4197-4203	design	_
25-3	4204-4212	Eligible	_
25-4	4213-4225	participants	_
25-5	4226-4230	were	_
25-6	4231-4236	asked	_
25-7	4237-4239	to	_
25-8	4240-4248	complete	_
25-9	4249-4256	several	_
25-10	4257-4271	questionnaires	_
25-11	4272-4278	before	_
25-12	4279-4289	performing	_
25-13	4290-4298	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-14	4299-4308	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-15	4309-4316	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-16	4317-4318	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-17	4319-4322	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-18	4323-4324	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-19	4325-4329	with	_
25-20	4330-4340	structural	_
25-21	4341-4344	and	_
25-22	4345-4355	functional	_
25-23	4356-4361	scans	_
25-24	4362-4363	.	_

26-1	4364-4367	The	_
26-2	4368-4380	psychometric	_
26-3	4381-4389	measures	_
26-4	4390-4398	included	_
26-5	4399-4402	the	_
26-6	4403-4409	social	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-7	4410-4416	phobia	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-8	4417-4422	scale	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-9	4423-4424	(	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-10	4425-4428	SPS	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-11	4429-4430	)	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-12	4431-4432	,	_
26-13	4433-4436	the	_
26-14	4437-4443	social	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-15	4444-4455	interaction	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-16	4456-4463	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-17	4464-4469	scale	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-18	4470-4471	(	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-19	4472-4476	SIAS	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-20	4477-4478	)	http://maven.renci.org/NeuroBridge/neurobridge#SocialFunctionRatingScale
26-21	4479-4480	,	_
26-22	4481-4484	the	_
26-23	4485-4494	rejection	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-24	4495-4506	sensitivity	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-25	4507-4520	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-26	4521-4522	(	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-27	4523-4526	RSQ	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-28	4527-4528	)	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalActivityQuestionnaire
26-29	4529-4532	and	_
26-30	4533-4536	the	_
26-31	4537-4542	brief	_
26-32	4543-4550	symptom	_
26-33	4551-4560	inventory	_
26-34	4561-4562	(	_
26-35	4563-4566	BSI	_
26-36	4567-4568	)	_
26-37	4569-4570	.	_

27-1	4571-4574	All	_
27-2	4575-4587	participants	_
27-3	4588-4597	underwent	_
27-4	4598-4608	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
27-5	4609-4612	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
27-6	4613-4621	scanning	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
27-7	4622-4625	and	_
27-8	4626-4635	performed	_
27-9	4636-4638	an	_
27-10	4639-4643	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-11	4644-4653	Cyberball	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-12	4654-4658	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-13	4659-4663	that	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-14	4664-4673	simulates	_
27-15	4674-4680	social	_
27-16	4681-4690	inclusion	_
27-17	4691-4694	and	_
27-18	4695-4701	social	_
27-19	4702-4711	exclusion	_
27-20	4712-4717	while	_
27-21	4718-4726	applying	_
27-22	4727-4734	painful	_
27-23	4735-4738	and	_
27-24	4739-4746	neutral	_
27-25	4747-4756	reference	_
27-26	4757-4768	temperature	_
27-27	4769-4776	stimuli	_
27-28	4777-4779	as	_
27-29	4780-4784	used	_
27-30	4785-4787	in	_
27-31	4788-4796	previous	_
27-32	4797-4804	studies	_
27-33	4805-4806	.	_

28-1	4807-4810	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-2	4811-4822	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-3	4823-4838	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-4	4839-4849	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-5	4850-4855	scans	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-6	4856-4861	using	_
28-7	4862-4863	a	_
28-8	4864-4875	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-9	4876-4878	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-10	4879-4901	magnetization-prepared	_
28-11	4902-4907	rapid	_
28-12	4908-4919	acquisition	_
28-13	4920-4933	gradient-echo	_
28-14	4934-4943	seq-uence	_
28-15	4944-4945	(	_
28-16	4946-4947	1	_
28-17	4948-4949	×	_
28-18	4950-4951	1	_
28-19	4952-4953	×	_
28-20	4954-4955	1	_
28-21	4956-4959	mm3	_
28-22	4960-4965	voxel	_
28-23	4966-4970	size	_
28-24	4971-4972	,	_
28-25	4973-4978	slice	_
28-26	4979-4988	thickness	_
28-27	4989-4990	1	_
28-28	4991-4993	mm	_
28-29	4994-4995	,	_
28-30	4996-5001	Field	_
28-31	5002-5004	of	_
28-32	5005-5009	view	_
28-33	5010-5011	(	_
28-34	5012-5015	FOV	_
28-35	5016-5017	)	_
28-36	5018-5021	256	_
28-37	5022-5023	×	_
28-38	5024-5027	256	_
28-39	5028-5030	mm	_
28-40	5031-5032	,	_
28-41	5033-5043	Repetition	_
28-42	5044-5048	Time	_
28-43	5049-5050	(	_
28-44	5051-5053	TR	_
28-45	5054-5055	)	_
28-46	5056-5057	=	_
28-47	5058-5062	2300	_
28-48	5063-5065	ms	_
28-49	5066-5067	,	_
28-50	5068-5072	Echo	_
28-51	5073-5077	Time	_
28-52	5078-5079	(	_
28-53	5080-5082	TE	_
28-54	5083-5084	)	_
28-55	5085-5086	=	_
28-56	5087-5091	3.03	_
28-57	5092-5094	ms	_
28-58	5095-5096	,	_
28-59	5097-5106	Inversion	_
28-60	5107-5111	Time	_
28-61	5112-5113	(	_
28-62	5114-5116	TI	_
28-63	5117-5118	)	_
28-64	5119-5120	=	_
28-65	5121-5124	900	_
28-66	5125-5127	ms	_
28-67	5128-5129	)	_
28-68	5130-5134	were	_
28-69	5135-5144	performed	_
28-70	5145-5150	using	_
28-71	5151-5152	a	_
28-72	5153-5154	3	_
28-73	5155-5156	T	_
28-74	5157-5167	whole-body	_
28-75	5168-5177	tomograph	_
28-76	5178-5179	(	_
28-77	5180-5188	MAGNETOM	_
28-78	5189-5193	Trio	_
28-79	5194-5195	,	_
28-80	5196-5203	Siemens	_
28-81	5204-5211	Medical	_
28-82	5212-5219	Systems	_
28-83	5220-5221	,	_
28-84	5222-5230	Erlangen	_
28-85	5231-5232	,	_
28-86	5233-5240	Germany	_
28-87	5241-5242	)	_
28-88	5243-5244	.	_

29-1	5245-5248	VBM	_
29-2	5249-5263	pre-processing	_
29-3	5264-5267	and	_
29-4	5268-5279	statistical	_
29-5	5280-5288	analyses	_
29-6	5289-5292	All	_
29-7	5293-5298	image	_
29-8	5299-5307	analyses	_
29-9	5308-5310	of	_
29-10	5311-5321	structural	_
29-11	5322-5326	data	_
29-12	5327-5331	were	_
29-13	5332-5341	conducted	_
29-14	5342-5347	using	_
29-15	5348-5351	the	_
29-16	5352-5358	latest	_
29-17	5359-5366	version	_
29-18	5367-5369	of	_
29-19	5370-5373	the	_
29-20	5374-5385	statistical	_
29-21	5386-5396	parametric	_
29-22	5397-5404	mapping	_
29-23	5405-5413	software	_
29-24	5414-5415	(	_
29-25	5416-5419	SPM	_
29-26	5420-5421	)	_
29-27	5422-5425	for	_
29-28	5426-5432	Matlab	_
29-29	5433-5434	(	_
29-30	5435-5442	version	_
29-31	5443-5445	12	_
29-32	5446-5447	,	_
29-33	5448-5456	Wellcome	_
29-34	5457-5467	Department	_
29-35	5468-5470	of	_
29-36	5471-5480	Cognitive	_
29-37	5481-5490	Neurology	_
29-38	5491-5492	,	_
29-39	5493-5499	London	_
29-40	5500-5501	,	_
29-41	5502-5504	UK	_
29-42	5505-5506	)	_
29-43	5507-5508	.	_

30-1	5509-5516	Current	_
30-2	5517-5531	methodological	_
30-3	5532-5539	studies	_
30-4	5540-5549	indicated	_
30-5	5550-5554	that	_
30-6	5555-5558	the	_
30-7	5559-5572	Computational	_
30-8	5573-5580	Anatomy	_
30-9	5581-5588	Toolbox	_
30-10	5589-5590	(	_
30-11	5591-5596	CAT12	_
30-12	5597-5598	,	_
30-13	5599-5603	http	_
30-14	5604-5605	:	_
30-15	5606-5644	//www.neuro.uni-jena.de/cat/index.html	_
30-16	5645-5646	)	_
30-17	5647-5650	for	_
30-18	5651-5656	SPM12	_
30-19	5657-5665	provides	_
30-20	5666-5667	a	_
30-21	5668-5672	more	_
30-22	5673-5681	accurate	_
30-23	5682-5692	volumetric	_
30-24	5693-5701	analysis	_
30-25	5702-5704	of	_
30-26	5705-5710	brain	_
30-27	5711-5718	regions	_
30-28	5719-5722	and	_
30-29	5723-5725	is	_
30-30	5726-5730	more	_
30-31	5731-5737	robust	_
30-32	5738-5741	and	_
30-33	5742-5750	accurate	_
30-34	5751-5758	against	_
30-35	5759-5769	volumetric	_
30-36	5770-5781	alterations	_
30-37	5782-5786	than	_
30-38	5787-5790	the	_
30-39	5791-5795	VBM8	_
30-40	5796-5803	toolbox	_
30-41	5804-5805	.	_

31-1	5806-5817	Considering	_
31-2	5818-5823	these	_
31-3	5824-5832	findings	_
31-4	5833-5834	,	_
31-5	5835-5837	we	_
31-6	5838-5847	performed	_
31-7	5848-5851	our	_
31-8	5852-5855	VBM	_
31-9	5856-5864	analyses	_
31-10	5865-5870	using	_
31-11	5871-5874	the	_
31-12	5875-5880	CAT12	_
31-13	5881-5888	toolbox	_
31-14	5889-5892	for	_
31-15	5893-5898	SPM12	_
31-16	5899-5900	,	_
31-17	5901-5909	applying	_
31-18	5910-5913	the	_
31-19	5914-5921	default	_
31-20	5922-5930	settings	_
31-21	5931-5934	and	_
31-22	5935-5945	proceeding	_
31-23	5946-5955	according	_
31-24	5956-5958	to	_
31-25	5959-5962	the	_
31-26	5963-5970	authors	_
31-27	5971-5972	’	_
31-28	5973-5979	manual	_
31-29	5980-5981	.	_

32-1	5982-5988	Before	_
32-2	5989-5994	image	_
32-3	5995-6003	analyses	_
32-4	6004-6005	,	_
32-5	6006-6009	all	_
32-6	6010-6015	image	_
32-7	6016-6024	datasets	_
32-8	6025-6029	were	_
32-9	6030-6039	inspected	_
32-10	6040-6042	by	_
32-11	6043-6045	at	_
32-12	6046-6051	least	_
32-13	6052-6055	one	_
32-14	6056-6063	medical	_
32-15	6064-6073	technical	_
32-16	6074-6083	radiology	_
32-17	6084-6093	assistant	_
32-18	6094-6096	to	_
32-19	6097-6102	check	_
32-20	6103-6106	for	_
32-21	6107-6110	any	_
32-22	6111-6116	gross	_
32-23	6117-6127	structural	_
32-24	6128-6141	abnormalities	_
32-25	6142-6144	or	_
32-26	6145-6152	imaging	_
32-27	6153-6162	artifacts	_
32-28	6163-6166	and	_
32-29	6167-6175	referred	_
32-30	6176-6178	to	_
32-31	6179-6180	a	_
32-32	6181-6197	neuroradiologist	_
32-33	6198-6200	if	_
32-34	6201-6210	necessary	_
32-35	6211-6212	.	_

33-1	6213-6216	All	_
33-2	6217-6219	3D	_
33-3	6220-6231	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-4	6232-6235	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-5	6236-6241	scans	_
33-6	6242-6246	were	_
33-7	6247-6257	normalized	_
33-8	6258-6263	using	_
33-9	6264-6266	an	_
33-10	6267-6273	affine	_
33-11	6274-6286	registration	_
33-12	6287-6295	followed	_
33-13	6296-6298	by	_
33-14	6299-6309	non-linear	_
33-15	6310-6322	registration	_
33-16	6323-6324	,	_
33-17	6325-6334	corrected	_
33-18	6335-6338	for	_
33-19	6339-6343	bias	_
33-20	6344-6349	field	_
33-21	6350-6363	inhomogeneity	_
33-22	6364-6367	and	_
33-23	6368-6372	then	_
33-24	6373-6382	segmented	_
33-25	6383-6387	into	_
33-26	6388-6390	GM	_
33-27	6391-6392	,	_
33-28	6393-6398	white	_
33-29	6399-6405	matter	_
33-30	6406-6407	(	_
33-31	6408-6410	WM	_
33-32	6411-6412	)	_
33-33	6413-6416	and	_
33-34	6417-6430	cerebrospinal	_
33-35	6431-6436	fluid	_
33-36	6437-6447	components	_
33-37	6448-6449	.	_

34-1	6450-6452	We	_
34-2	6453-6457	used	_
34-3	6458-6461	the	_
34-4	6462-6475	Diffeomorphic	_
34-5	6476-6484	Anatomic	_
34-6	6485-6497	Registration	_
34-7	6498-6505	Through	_
34-8	6506-6519	Exponentiated	_
34-9	6520-6523	Lie	_
34-10	6524-6525	(	_
34-11	6526-6532	DARTEL	_
34-12	6533-6534	)	_
34-13	6535-6542	algebra	_
34-14	6543-6552	algorithm	_
34-15	6553-6555	to	_
34-16	6556-6565	normalize	_
34-17	6566-6569	the	_
34-18	6570-6579	segmented	_
34-19	6580-6585	scans	_
34-20	6586-6590	into	_
34-21	6591-6592	a	_
34-22	6593-6601	standard	_
34-23	6602-6610	Montreal	_
34-24	6611-6623	Neurological	_
34-25	6624-6633	Institute	_
34-26	6634-6635	(	_
34-27	6636-6639	MNI	_
34-28	6640-6641	)	_
34-29	6642-6647	space	_
34-30	6648-6649	.	_

35-1	6650-6658	Compared	_
35-2	6659-6661	to	_
35-3	6662-6665	the	_
35-4	6666-6678	conventional	_
35-5	6679-6688	algorithm	_
35-6	6689-6690	,	_
35-7	6691-6694	the	_
35-8	6695-6701	DARTEL	_
35-9	6702-6710	approach	_
35-10	6711-6719	provides	_
35-11	6720-6724	more	_
35-12	6725-6732	precise	_
35-13	6733-6740	spatial	_
35-14	6741-6754	normalization	_
35-15	6755-6757	to	_
35-16	6758-6761	the	_
35-17	6762-6770	template	_
35-18	6771-6775	than	_
35-19	6776-6784	standard	_
35-20	6785-6797	registration	_
35-21	6798-6805	methods	_
35-22	6806-6807	.	_

36-1	6808-6817	Following	_
36-2	6818-6822	this	_
36-3	6823-6827	step	_
36-4	6828-6829	,	_
36-5	6830-6836	images	_
36-6	6837-6841	were	_
36-7	6842-6850	visually	_
36-8	6851-6860	inspected	_
36-9	6861-6864	for	_
36-10	6865-6871	sample	_
36-11	6872-6883	homogeneity	_
36-12	6884-6886	of	_
36-13	6887-6890	the	_
36-14	6891-6901	unsmoothed	_
36-15	6902-6906	data	_
36-16	6907-6908	.	_

37-1	6909-6913	This	_
37-2	6914-6917	was	_
37-3	6918-6927	evaluated	_
37-4	6928-6933	using	_
37-5	6934-6937	the	_
37-6	6938-6947	procedure	_
37-7	6948-6956	included	_
37-8	6957-6959	in	_
37-9	6960-6963	the	_
37-10	6964-6969	CAT12	_
37-11	6970-6977	toolbox	_
37-12	6978-6979	.	_

38-1	6980-6991	Mahalanobis	_
38-2	6992-7000	distance	_
38-3	7001-7002	,	_
38-4	7003-7012	combining	_
38-5	7013-7016	the	_
38-6	7017-7021	mean	_
38-7	7022-7033	correlation	_
38-8	7034-7037	and	_
38-9	7038-7046	weighted	_
38-10	7047-7054	overall	_
38-11	7055-7060	image	_
38-12	7061-7068	quality	_
38-13	7069-7073	were	_
38-14	7074-7083	inspected	_
38-15	7084-7087	and	_
38-16	7088-7096	outliers	_
38-17	7097-7098	(	_
38-18	7099-7100	>	_
38-19	7101-7102	2	_
38-20	7103-7111	standard	_
38-21	7112-7122	deviations	_
38-22	7123-7124	)	_
38-23	7125-7133	excluded	_
38-24	7134-7138	from	_
38-25	7139-7146	further	_
38-26	7147-7155	analyses	_
38-27	7156-7157	(	_
38-28	7158-7159	n	_
38-29	7160-7161	=	_
38-30	7162-7163	3	_
38-31	7164-7165	)	_
38-32	7166-7167	.	_

39-1	7168-7171	The	_
39-2	7172-7181	remaining	_
39-3	7182-7191	segmented	_
39-4	7192-7193	,	_
39-5	7194-7203	modulated	_
39-6	7204-7207	and	_
39-7	7208-7218	normalized	_
39-8	7219-7227	datasets	_
39-9	7228-7232	were	_
39-10	7233-7241	smoothed	_
39-11	7242-7247	using	_
39-12	7248-7250	an	_
39-13	7251-7252	8	_
39-14	7253-7255	mm	_
39-15	7256-7266	full-width	_
39-16	7267-7279	half-maximum	_
39-17	7280-7288	Gaussian	_
39-18	7289-7298	smoothing	_
39-19	7299-7305	kernel	_
39-20	7306-7309	and	_
39-21	7310-7314	then	_
39-22	7315-7318	fed	_
39-23	7319-7323	into	_
39-24	7324-7336	second-level	_
39-25	7337-7347	two-sample	_
39-26	7348-7354	t-test	_
39-27	7355-7363	analyses	_
39-28	7364-7365	,	_
39-29	7366-7377	considering	_
39-30	7378-7383	total	_
39-31	7384-7396	intracranial	_
39-32	7397-7403	volume	_
39-33	7404-7405	(	_
39-34	7406-7409	TIV	_
39-35	7410-7411	)	_
39-36	7412-7415	and	_
39-37	7416-7419	age	_
39-38	7420-7422	as	_
39-39	7423-7433	covariates	_
39-40	7434-7435	.	_

40-1	7436-7438	In	_
40-2	7439-7444	order	_
40-3	7445-7447	to	_
40-4	7448-7455	control	_
40-5	7456-7459	for	_
40-6	7460-7468	multiple	_
40-7	7469-7480	comparisons	_
40-8	7481-7482	,	_
40-9	7483-7484	a	_
40-10	7485-7493	combined	_
40-11	7494-7508	cluster-extent	_
40-12	7509-7512	and	_
40-13	7513-7523	voxel-wise	_
40-14	7524-7533	threshold	_
40-15	7534-7535	,	_
40-16	7536-7549	corresponding	_
40-17	7550-7552	to	_
40-18	7553-7554	a	_
40-19	7555-7566	family-wise	_
40-20	7567-7572	error	_
40-21	7573-7574	(	_
40-22	7575-7578	FWE	_
40-23	7579-7580	)	_
40-24	7581-7585	rate	_
40-25	7586-7588	of	_
40-26	7589-7593	pFWE	_
40-27	7594-7595	<	_
40-28	7596-7600	0.05	_
40-29	7601-7602	,	_
40-30	7603-7606	was	_
40-31	7607-7617	determined	_
40-32	7618-7623	using	_
40-33	7624-7627	the	_
40-34	7628-7636	AlphaSim	_
40-35	7637-7643	module	_
40-36	7644-7646	of	_
40-37	7647-7650	the	_
40-38	7651-7659	NeuroElf	_
40-39	7660-7667	toolbox	_
40-40	7668-7669	(	_
40-41	7670-7686	www.neuroelf.net	_
40-42	7687-7688	)	_
40-43	7689-7692	for	_
40-44	7693-7699	Matlab	_
40-45	7700-7701	.	_

41-1	7702-7705	For	_
41-2	7706-7707	a	_
41-3	7708-7715	pre-set	_
41-4	7716-7726	voxel-wise	_
41-5	7727-7736	threshold	_
41-6	7737-7739	of	_
41-7	7740-7741	P	_
41-8	7742-7743	<	_
41-9	7744-7749	0.001	_
41-10	7750-7751	,	_
41-11	7752-7755	the	_
41-12	7756-7764	AlphaSim	_
41-13	7765-7774	procedure	_
41-14	7775-7785	determined	_
41-15	7786-7787	a	_
41-16	7788-7802	cluster-extent	_
41-17	7803-7812	threshold	_
41-18	7813-7815	of	_
41-19	7816-7819	103	_
41-20	7820-7826	voxels	_
41-21	7827-7828	(	_
41-22	7829-7835	10.000	_
41-23	7836-7841	Monte	_
41-24	7842-7847	Carlo	_
41-25	7848-7859	simulations	_
41-26	7860-7861	,	_
41-27	7862-7871	smoothing	_
41-28	7872-7878	kernel	_
41-29	7879-7881	of	_
41-30	7882-7883	x	_
41-31	7884-7885	=	_
41-32	7886-7887	8	_
41-33	7888-7890	mm	_
41-34	7891-7892	,	_
41-35	7893-7894	y	_
41-36	7895-7896	=	_
41-37	7897-7898	8	_
41-38	7899-7901	mm	_
41-39	7902-7903	,	_
41-40	7904-7905	z	_
41-41	7906-7907	=	_
41-42	7908-7909	8	_
41-43	7910-7912	mm	_
41-44	7913-7914	)	_
41-45	7915-7916	.	_

42-1	7917-7919	In	_
42-2	7920-7925	order	_
42-3	7926-7928	to	_
42-4	7929-7935	follow	_
42-5	7936-7938	up	_
42-6	7939-7941	on	_
42-7	7942-7945	the	_
42-8	7946-7953	results	_
42-9	7954-7956	of	_
42-10	7957-7960	the	_
42-11	7961-7972	whole-brain	_
42-12	7973-7981	analyses	_
42-13	7982-7983	,	_
42-14	7984-7996	standardized	_
42-15	7997-8007	anatomical	_
42-16	8008-8013	masks	_
42-17	8014-8018	were	_
42-18	8019-8023	used	_
42-19	8024-8026	to	_
42-20	8027-8034	extract	_
42-21	8035-8037	GM	_
42-22	8038-8044	volume	_
42-23	8045-8049	data	_
42-24	8050-8054	from	_
42-25	8055-8058	the	_
42-26	8059-8069	respective	_
42-27	8070-8075	brain	_
42-28	8076-8083	regions	_
42-29	8084-8088	that	_
42-30	8089-8095	showed	_
42-31	8096-8107	significant	_
42-32	8108-8113	group	_
42-33	8114-8121	effects	_
42-34	8122-8123	(	_
42-35	8124-8132	contrast	_
42-36	8133-8134	:	_
42-37	8135-8142	healthy	_
42-38	8143-8155	participants	_
42-39	8156-8157	>	_
42-40	8158-8161	OMT	_
42-41	8162-8170	patients	_
42-42	8171-8172	)	_
42-43	8173-8174	.	_

43-1	8175-8178	The	_
43-2	8179-8184	masks	_
43-3	8185-8189	that	_
43-4	8190-8197	defined	_
43-5	8198-8201	the	_
43-6	8202-8209	regions	_
43-7	8210-8212	of	_
43-8	8213-8221	interest	_
43-9	8222-8223	(	_
43-10	8224-8227	ROI	_
43-11	8228-8229	)	_
43-12	8230-8234	were	_
43-13	8235-8242	derived	_
43-14	8243-8247	from	_
43-15	8248-8251	the	_
43-16	8252-8259	Hammers	_
43-17	8260-8265	brain	_
43-18	8266-8271	atlas	_
43-19	8272-8273	.	_

44-1	8274-8286	Specifically	_
44-2	8287-8288	,	_
44-3	8289-8291	GM	_
44-4	8292-8298	volume	_
44-5	8299-8303	data	_
44-6	8304-8308	were	_
44-7	8309-8318	extracted	_
44-8	8319-8323	from	_
44-9	8324-8327	the	_
44-10	8328-8329	(	_
44-11	8330-8331	i	_
44-12	8332-8333	)	_
44-13	8334-8338	left	_
44-14	8339-8345	insula	_
44-15	8346-8347	[	_
44-16	8348-8352	BA13	_
44-17	8353-8354	]	_
44-18	8355-8356	,	_
44-19	8357-8358	(	_
44-20	8359-8361	ii	_
44-21	8362-8363	)	_
44-22	8364-8369	right	_
44-23	8370-8376	insula	_
44-24	8377-8378	[	_
44-25	8379-8383	BA13	_
44-26	8384-8385	]	_
44-27	8386-8387	,	_
44-28	8388-8389	(	_
44-29	8390-8393	iii	_
44-30	8394-8395	)	_
44-31	8396-8400	left	_
44-32	8401-8409	inferior	_
44-33	8410-8417	frontal	_
44-34	8418-8423	gyrus	_
44-35	8424-8425	[	_
44-36	8426-8430	BA47	_
44-37	8431-8432	]	_
44-38	8433-8436	and	_
44-39	8437-8438	(	_
44-40	8439-8441	iv	_
44-41	8442-8443	)	_
44-42	8444-8449	right	_
44-43	8450-8458	inferior	_
44-44	8459-8466	frontal	_
44-45	8467-8472	gyrus	_
44-46	8473-8474	[	_
44-47	8475-8479	BA47	_
44-48	8480-8481	]	_
44-49	8482-8487	using	_
44-50	8488-8491	the	_
44-51	8492-8500	standard	_
44-52	8501-8510	procedure	_
44-53	8511-8513	of	_
44-54	8514-8517	the	_
44-55	8518-8523	CAT12	_
44-56	8524-8531	toolbox	_
44-57	8532-8535	for	_
44-58	8536-8538	GM	_
44-59	8539-8545	volume	_
44-60	8546-8550	data	_
44-61	8551-8561	extraction	_
44-62	8562-8566	from	_
44-63	8567-8571	ROIs	_
44-64	8572-8573	.	_

45-1	8574-8578	Data	_
45-2	8579-8583	were	_
45-3	8584-8592	imported	_
45-4	8593-8597	into	_
45-5	8598-8602	SPSS	_
45-6	8603-8610	version	_
45-7	8611-8615	24.0	_
45-8	8616-8619	for	_
45-9	8620-8627	further	_
45-10	8628-8639	correlation	_
45-11	8640-8648	analyses	_
45-12	8649-8650	(	_
45-13	8651-8655	SPSS	_
45-14	8656-8657	,	_
45-15	8658-8661	IBM	_
45-16	8662-8667	Corp.	_
45-17	8668-8669	,	_
45-18	8670-8676	Somers	_
45-19	8677-8678	,	_
45-20	8679-8681	NY	_
45-21	8682-8683	,	_
45-22	8684-8687	USA	_
45-23	8688-8689	)	_
45-24	8690-8691	.	_

46-1	8692-8703	Statistical	_
46-2	8704-8712	analyses	_
46-3	8713-8726	Demographical	_
46-4	8727-8731	data	_
46-5	8732-8735	and	_
46-6	8736-8748	psychometric	_
46-7	8749-8755	scales	_
46-8	8756-8760	were	_
46-9	8761-8769	analyzed	_
46-10	8770-8775	using	_
46-11	8776-8780	SPSS	_
46-12	8781-8785	24.0	_
46-13	8786-8789	and	_
46-14	8790-8792	by	_
46-15	8793-8801	applying	_
46-16	8802-8812	two-sample	_
46-17	8813-8820	t-tests	_
46-18	8821-8824	and	_
46-19	8825-8836	chi-squared	_
46-20	8837-8842	tests	_
46-21	8843-8844	.	_

47-1	8845-8850	Group	_
47-2	8851-8862	differences	_
47-3	8863-8865	in	_
47-4	8866-8868	GM	_
47-5	8869-8875	volume	_
47-6	8876-8880	were	_
47-7	8881-8889	analyzed	_
47-8	8890-8895	using	_
47-9	8896-8906	two-sample	_
47-10	8907-8914	t-tests	_
47-11	8915-8925	correcting	_
47-12	8926-8929	for	_
47-13	8930-8933	TIV	_
47-14	8934-8937	and	_
47-15	8938-8941	age	_
47-16	8942-8943	.	_

48-1	8944-8951	Results	_
48-2	8952-8955	are	_
48-3	8956-8964	depicted	_
48-4	8965-8967	in	_
48-5	8968-8973	Table	_
48-6	8974-8975	1	_
48-7	8976-8977	.	_

49-1	8978-8990	Associations	_
49-2	8991-8998	between	_
49-3	8999-9001	GM	_
49-4	9002-9008	volume	_
49-5	9009-9011	in	_
49-6	9012-9017	areas	_
49-7	9018-9022	that	_
49-8	9023-9032	displayed	_
49-9	9033-9044	significant	_
49-10	9045-9056	whole-brain	_
49-11	9057-9068	differences	_
49-12	9069-9071	in	_
49-13	9072-9082	two-sample	_
49-14	9083-9090	t-tests	_
49-15	9091-9098	between	_
49-16	9099-9115	opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
49-17	9116-9124	patients	_
49-18	9125-9128	and	_
49-19	9129-9136	healthy	_
49-20	9137-9149	participants	_
49-21	9150-9151	(	_
49-22	9152-9155	i.e	_
49-23	9156-9157	.	_

50-1	9158-9167	bilateral	_
50-2	9168-9174	insula	_
50-3	9175-9178	and	_
50-4	9179-9184	right	_
50-5	9185-9193	inferior	_
50-6	9194-9201	frontal	_
50-7	9202-9207	gyrus	_
50-8	9208-9209	)	_
50-9	9210-9213	and	_
50-10	9214-9226	psychometric	_
50-11	9227-9233	scales	_
50-12	9234-9242	covering	_
50-13	9243-9249	social	_
50-14	9250-9257	anxiety	_
50-15	9258-9261	and	_
50-16	9262-9271	rejection	_
50-17	9272-9283	sensitivity	_
50-18	9284-9285	(	_
50-19	9286-9290	SIAS	_
50-20	9291-9292	,	_
50-21	9293-9296	RSQ	_
50-22	9297-9298	,	_
50-23	9299-9302	SPS	_
50-24	9303-9304	)	_
50-25	9305-9308	and	_
50-26	9309-9318	Cyberball	_
50-27	9319-9331	task-related	_
50-28	9332-9339	changes	_
50-29	9340-9342	in	_
50-30	9343-9351	feelings	_
50-31	9352-9354	of	_
50-32	9355-9360	being	_
50-33	9361-9369	excluded	_
50-34	9370-9372	or	_
50-35	9373-9381	included	_
50-36	9382-9386	were	_
50-37	9387-9399	investigated	_
50-38	9400-9405	using	_
50-39	9406-9413	partial	_
50-40	9414-9425	correlation	_
50-41	9426-9434	analyses	_
50-42	9435-9436	,	_
50-43	9437-9448	controlling	_
50-44	9449-9452	for	_
50-45	9453-9456	age	_
50-46	9457-9460	and	_
50-47	9461-9464	TIV	_
50-48	9465-9466	(	_
50-49	9467-9474	because	_
50-50	9475-9479	both	_
50-51	9480-9484	were	_
50-52	9485-9492	related	_
50-53	9493-9495	to	_
50-54	9496-9498	GM	_
50-55	9499-9505	volume	_
50-56	9506-9517	variability	_
50-57	9518-9520	in	_
50-58	9521-9529	previous	_
50-59	9530-9537	studies	_
50-60	9538-9539	)	_
50-61	9540-9541	.	_

51-1	9542-9547	Prior	_
51-2	9548-9549	,	_
51-3	9550-9561	exploratory	_
51-4	9562-9566	data	_
51-5	9567-9575	analyses	_
51-6	9576-9580	were	_
51-7	9581-9590	conducted	_
51-8	9591-9593	to	_
51-9	9594-9602	identify	_
51-10	9603-9612	potential	_
51-11	9613-9621	outliers	_
51-12	9622-9623	.	_

52-1	9624-9627	One	_
52-2	9628-9635	patient	_
52-3	9636-9639	had	_
52-4	9640-9643	low	_
52-5	9644-9650	values	_
52-6	9651-9653	on	_
52-7	9654-9657	the	_
52-8	9658-9666	variable	_
52-9	9667-9675	encoding	_
52-10	9676-9680	left	_
52-11	9681-9687	insula	_
52-12	9688-9690	GM	_
52-13	9691-9697	volume	_
52-14	9698-9699	(	_
52-15	9700-9701	>	_
52-16	9702-9706	1.5×	_
52-17	9707-9720	interquartile	_
52-18	9721-9726	range	_
52-19	9727-9728	)	_
52-20	9729-9730	.	_

53-1	9731-9733	As	_
53-2	9734-9737	the	_
53-3	9738-9748	inspection	_
53-4	9749-9751	of	_
53-5	9752-9755	the	_
53-6	9756-9759	raw	_
53-7	9760-9767	imaging	_
53-8	9768-9772	data	_
53-9	9773-9776	and	_
53-10	9777-9791	pre-processing	_
53-11	9792-9799	quality	_
53-12	9800-9807	indices	_
53-13	9808-9817	indicated	_
53-14	9818-9822	good	_
53-15	9823-9830	quality	_
53-16	9831-9833	of	_
53-17	9834-9837	the	_
53-18	9838-9848	anatomical	_
53-19	9849-9853	data	_
53-20	9854-9855	,	_
53-21	9856-9858	we	_
53-22	9859-9869	considered	_
53-23	9870-9874	this	_
53-24	9875-9880	value	_
53-25	9881-9883	to	_
53-26	9884-9891	reflect	_
53-27	9892-9895	the	_
53-28	9896-9900	true	_
53-29	9901-9906	value	_
53-30	9907-9909	of	_
53-31	9910-9913	the	_
53-32	9914-9925	participant	_
53-33	9926-9929	and	_
53-34	9930-9935	opted	_
53-35	9936-9938	to	_
53-36	9939-9946	include	_
53-37	9947-9951	that	_
53-38	9952-9963	participant	_
53-39	9964-9966	in	_
53-40	9967-9970	the	_
53-41	9971-9982	correlation	_
53-42	9983-9991	analyses	_
53-43	9992-9993	.	_

54-1	9994-10001	Partial	_
54-2	10002-10014	correlations	_
54-3	10015-10022	between	_
54-4	10023-10024	(	_
54-5	10025-10026	i	_
54-6	10027-10028	)	_
54-7	10029-10041	psychometric	_
54-8	10042-10048	scales	_
54-9	10049-10052	and	_
54-10	10053-10054	(	_
54-11	10055-10057	ii	_
54-12	10058-10059	)	_
54-13	10060-10070	subjective	_
54-14	10071-10078	ratings	_
54-15	10079-10081	of	_
54-16	10082-10091	inclusion	_
54-17	10092-10095	and	_
54-18	10096-10105	exclusion	_
54-19	10106-10112	during	_
54-20	10113-10116	the	_
54-21	10117-10126	Cyberball	_
54-22	10127-10131	task	_
54-23	10132-10141	inclusion	_
54-24	10142-10151	condition	_
54-25	10152-10155	and	_
54-26	10156-10158	GM	_
54-27	10159-10165	volume	_
54-28	10166-10170	were	_
54-29	10171-10180	corrected	_
54-30	10181-10184	for	_
54-31	10185-10193	multiple	_
54-32	10194-10205	comparisons	_
54-33	10206-10207	[	_
54-34	10208-10211	i.e	_
54-35	10212-10213	.	_

55-1	10214-10215	(	_
55-2	10216-10217	i	_
55-3	10218-10219	)	_
55-4	10220-10224	four	_
55-5	10225-10236	independent	_
55-6	10237-10244	partial	_
55-7	10245-10257	correlations	_
55-8	10258-10261	per	_
55-9	10262-10267	brain	_
55-10	10268-10272	area	_
55-11	10273-10274	,	_
55-12	10275-10279	left	_
55-13	10280-10286	insula	_
55-14	10287-10288	,	_
55-15	10289-10294	right	_
55-16	10295-10301	insula	_
55-17	10302-10303	,	_
55-18	10304-10312	inferior	_
55-19	10313-10320	frontal	_
55-20	10321-10326	gyrus	_
55-21	10327-10328	,	_
55-22	10329-10330	(	_
55-23	10331-10333	ii	_
55-24	10334-10335	)	_
55-25	10336-10339	two	_
55-26	10340-10351	independent	_
55-27	10352-10359	partial	_
55-28	10360-10372	correlations	_
55-29	10373-10376	per	_
55-30	10377-10382	brain	_
55-31	10383-10387	area	_
55-32	10388-10389	]	_
55-33	10390-10395	using	_
55-34	10396-10399	the	_
55-35	10400-10409	Benjamini	_
55-36	10410-10413	and	_
55-37	10414-10422	Hochberg	_
55-38	10423-10432	procedure	_
55-39	10433-10435	as	_
55-40	10436-10447	implemented	_
55-41	10448-10450	in	_
55-42	10451-10454	the	_
55-43	10455-10461	Matlab	_
55-44	10462-10463	‘	_
55-45	10464-10469	mafdr	_
55-46	10470-10471	’	_
55-47	10472-10480	function	_
55-48	10481-10482	.	_

